Skip to main content
NCBI home page
ACS Omega logoLink to ACS Omega
. 2019 Dec 30;5(1):252–264. doi: 10.1021/acsomega.9b02604

Synthesis and Antimicrobial Activity of Novel Piperidinyl Tetrahydrothieno[2,3-c]isoquinolines and Related Heterocycles

Remon M Zaki 1,*, Adel M Kamal El-Dean 1, Shaban M Radwan 1, Asmaa S A Sayed 1
PMCID: PMC6964266  PMID: 31956772

Abstract

graphic file with name ao9b02604_0007.jpg

A novel series of 1-amino-2-substituted-5-piperidinyl-6,7,8,9-tertahydrothieno[2,3-c]isoquinolines (4a–e) was synthesized upon treatment of 4-cyano-1-piperidinyl-5,6,7,8-tetrahydroisoquinline-3(2H)-thione (2) with α-halo carbonyl compounds such as chloroacetone, ethyl chloroacetate, 2-bromoacetophenone, chloroacetamide, and chloroacetanilide. Construction the pyrrolyl ring associated with the thienotetrahydroisoquinoline moiety was achieved by treatment of compounds 4a, b with 2,5-dimethoxytertahydrofuran in acetic acid. 1-Pyrrolyl-2-substituted-thieno[2,3-c]isoquinolines 5a and 5b which in turn were used as multipurpose precursors for synthesis of other new heterocycles. Assignments of the chemical structures of the respectively synthesized thienotetrahydroisoquinolines and their derivatives were established on the bases of elemental and spectral techniques (Fourier transform infrared, 1H NMR, 13C NMR, and mass spectroscopy). Furthermore, certain compounds were screened for their antimicrobial activity which revealed promising activities against various pathogenic strains of bacteria and fungi.

Introduction

The tetrahydroisoqunioline ring system is a privileged fundamental scaffold of various alkaloids isolated from natural sources and abundantly found in various plants, soils, and marine microorganisms.1 Molecules embedded with these scaffolds are important pharmaceutical intermediates in medicinal chemistry and have gained distinctive attention because of their broad spectrum of pharmacological properties. Many tetrahydroisoquinoline compounds are considered as antitumor,2,3 anticonvulsant, antithrombotic,4 analgesic,5 anti-inflammatory,6 antifungal, and antibacterial agents.7 Moreover, tetrahydroisoquinolines are useful compounds as antagonist to NMDA and D1 receptors,8 Parkinson’s disease,9 enzyme inhibitory actions for glucosidases,10 and monoamine oxidases.11 Isolated alkaloids from natural sources containing the tetrahydroisoquinoline moiety are broadly abundant in many biologically active compounds (Figure 1). Higenamine 1 extracted from the leaves of Aristolochia brasiliensis has been recognized as an agonist for the β2-adrenergic receptor12−14 and antimycobacterial12 and anti-inflammatory drugs.14,15 The complex α-substituted tetrahydroisoquinoline, Noscapine 2, revealed an antiproliferative activity against human prostate cancer cells.16,17 Oleracin E 3 has been established as an antioxidant and antidepressant agent.18,19 The catechol-derived tetrahydroisoquinoline alkaloid Salsolinol 4 plays an important role in pathogenic treatment associated with Parkinson’s diseases.20−23 Despite thienoquinolines and thienoisoquinolines being poorly represented in nature, they are important compounds in medicinal chemistry. Related compounds exhibit antileukemic24 and antibacterial activities;25 also, they were proved as vasodilators.26

Figure 1.

Figure 1

Open in a new tab

Structures of naturally occurring and biologically active tetrahydroisoquinolines.

In the light of the prior biological activities of tetrahydroisoquinolines and in resumption of our project for synthesis of new heterocycles containing the thienotetrahydroisoquinolines moiety,27−34 we have announced here preparation of the new 1-amino-2-substituted and 1-pyrrolyl-2-substituted-5-piperidinyl-6,7,8,9-tetrahydrothieno[2,3-c]isoquinolines and their fused heterocycles which have proved promising antibacterial and antifungal activities parallel to the standard drugs.

Results and Discussion

Our strategy is initiated with synthesis of 3-thioxo-1-piperidinyl-5,6,7,8-tetrahydroisoquinoline-4-carbonitrile substrate (2) which is an essential intermediate for preparation of the new tetrahydrothieno[2,3-c]isoquinolines by the reaction of isothiochromene 1 with piperidine via Dimroth(35) rearrangement in an excellent yield. The thione 2 was permitted to react with several α-halo carbonyl compounds (e.g. chloroacetone, ethyl chloroacetate, 2-bromoacetophenone, chloroacetamide, and chloroacetanilide) in refluxing ethanol and fused sodium acetate to afford the corresponding S-alkylated products 3a–e, which in turn underwent Thorpe–Ziegler cyclization36 upon heating with sodium ethoxide solution in ethanol producing the target o-bifunctionally substituted thieno[2,3-c]isoquinolines 4a–e. The latter compounds were obtained via an alternative route, upon reaction of 2 with the mentioned α-halo carbonyl compounds using anhydrous potassium carbonate as a basic catalyst instead of sodium acetate. The products that were created by the two methods were identical in all features. Elucidation of the chemical structures of 4a–e was confirmed from their spectral analyses. Fourier transform infrared (FT-IR) of 4a revealed bands at 3449 and 3271 cm–1 specific for NH2 and at 1589 cm–1 characteristic for CO. 1H NMR in CDCl3 exhibited two singlets at δ 2.39 and 7.20 ppm attributed to CH3 and NH2 groups. 13C NMR of 4a displayed signal at δ 192.32 ppm for CO unique for the acetyl group (Scheme 1).

Scheme 1. Synthesis of 1-Amino-2-substituted-5-piperidinyl-6,7,8,9-tertahydrothieno[2,3-c]isoquinolines (4a–e).

Scheme 1

Open in a new tab

Furthermore, treatment of the amino-acetyl and amino-ester derivatives 4a and 4b with 2,5-dimethyl tetrahydrofuran afforded the corresponding pyrrolyl derivatives 5a and 5b. The IR spectrum of 5b emerged with the absence of bands at 3493 and 3337 distinctive to the NH2 group with a band at 1657 specific for the CO ester. 1H NMR of 5b affirmed the absence of the singlet signal attributed to NH2 in 4b and the presence of multiplet signals at δ 6.20–6.33 and 7.15–7.46 particular for the pyrrolyl protons, in addition to triplet and quartet signals at δ 1.34–1.38 and 4.28–4.33 characteristic for CH3 and CH2 of the ethoxyl group, respectively. 13C NMR in CDCl3 exhibited signals at 14.55, 60.06, and 166.08 specific for CH3, CH2, and CO of the ethoxyl group. The pyrrolyl acetyl 5a was used as a basic intermediate for production of new heterocycles. When the pyrrolyl acetyl 5a was subjected to react with dimethylformamide dimethylacetal (DMFDMA) in DMF, the corresponding dimethyl amino-2-propenone 6 was obtained. Similarly, condensation of 5a with different aromatic aldehydes developed formation of the corresponding chalcone derivatives 7a–c. 1H NMR of 7a emphasized disappearance of the signal at δ 1.95 ppm specific for CH3 of the acetyl group and emergence of multiplet signals at δ 7.33–7.45 particular for aromatic protons. The 13C NMR spectrum showed signals at 128.65–130.27 ppm characteristic for the carbon atoms of the phenyl ring. Also, the mass spectrum of 7a exhibited peaks at 467.34 and as a molecular ion and at 84.15 as a base peak. Therefore, reaction of chalcone 7a with phenyl hydrazine and hydroxyl amine hydrochloride afforded the pyrazolyl and isoxazolyl derivatives 8 and 9. The homogeneity of the chemical structures for the latter compounds was confirmed by elemental and spectral techniques. 1H NMR of compound 8 represented doublet and triplet signals at δ 3.63–3.70 and 5.03–5.18 attributed to CH2 and CHPh of pyrazole. Also, 13C NMR exhibited signals at δ 51.05 and 64.81 for CH2 and CH pyrazole (Scheme 2).

Scheme 2. Synthesis of the Pyrrolyl Derivatives 5a, b Starting with the Acetyl Derivative 5a To Synthesize Various Chalcones, Pyrazolyl, and Isoxazolyl Compounds 6–9.

Scheme 2

Open in a new tab

Moreover, hydrazinolysis of the ester 5b with hydrazine hydrate provided the corresponding carbohydrazide 10. 1H NMR in CDCl3 represented two singlets at δ 3.89 and 6.26 accredited to NH2 and NH. 13C NMR emerged signal at δ 162.70 specific for the CONH group. Cyclocondensation of the carbohydrazide 10 with acetyl acetone37 in ethanol produced first the corresponding pentylidene Schiff’s base 11 followed by cyclization upon reflux in acetic acid to produce the dimethyl pyrazolyl derivative 12 in a moderate yield. FT-IR of 12 showed absence of bands assigned to NH and COCH3 groups. The 1H NMR spectrum represented singlet signals at δ 1.27 and 1.65 ppm unique for the two pyrazolyl methyl groups. 13C NMR of 12 exhibited a signal at δ 164.90 particular for the carbonyl group. In a similar manner, condensation of the carbohydrazide 10 with triethylorthoformate in existence of catalytic acetic acid drops provided the ethoxymethylene carbohydrazide 13. FT-IR of 13 revealed the NH absorption band at 3332 cm–1. 1H NMR represented triplet and quartet signals at δ 1.31–1.34 and 4.00–4.05 specific for the ethoxyl group (Scheme 3).

Scheme 3. Synthesis and Cyclocondensation of the Carbohydrazide 10 with 1,3 Dicarbonyl Compounds, Triethylorthoformate Giving Compounds 11–13.

Scheme 3

Open in a new tab

Conclusions

In the current study, we have provided a facile approach for synthesis of unique piperidinyl tetrahydrothieno[2,3-c]isoquinolines based on various reactions of the pyrrolyl—acetyl 5a and pyrrolyl—ester derivatives 5b. The isolated products were easily purified by recrystallization from the proper solvents. Alternatively, most of the synthesized products revealed promising antibacterial and antifungal activities against various genera of bacteria and fungi. Therefore, this sophisticated strategy could be utilized for synthesis of compounds that are medicinally and pharmaceutically significant.

Biological Activity

Recently, developing new and more effective antimicrobial therapies have become one of the greatest concerns for human health, which has attracted considerable attention of the scientists worldwide as a result to the development of resistance to the present antimicrobial remedy. Therefore, one of the main targets of our study is synthesis of new compounds having superior importance in biological and medicinal chemistry. The selected compounds 5a, 6, 7a, 7b, and 7c were screened for their in vitro inhibitory effect versus a panel of pathogenic genera of Gram positive (Bacillus cereus and Staphylococcus aureus) and Gram negative bacteria (Pseudomonas aeruginosa and Escherichia coli) in addition to four strains of pathogenic fungi Geotrichum candidum, Candida albicans, Trichophyton rubrum, and Aspergillus flavus. The inhibition zones (mm) and minimum inhibitory concentration (MIC) (μg/mL) of the tested compounds were compared with amoxicillin and clotrimazole as antibacterial and antifungal reference medicines.

Antibacterial Activity

The antibacterial assessment results for the tested compounds indicated significant activity and were summarized in Table 1. Compounds 5a and 6 exhibited the highest activities against all genera of bacteria (MIC 7.0–9.0 μg/mL) parallel to amoxicillin (MIC 3.0–5.0 μg/mL). Compounds 5a, 6, and 7b represented the best activities against B. cereus with MIC (7.0–9.0 μg/mL) compared to amoxicillin (MIC 4.0 μg/mL), while compounds 7a and 7c displayed moderate effects. In case of S. aureus, all of the tested compounds revealed significant activities against all strains of Gram positive and Gram negative bacteria (MIC 8.0–9.0 μg/mL) with very close inhibition zones (15–19 mm) compared to the reference drug (21 mm and MIC 3.0 μg/mL). Alternatively, compounds 5a, 6, and 7b were found to be the most active derivatives versus P. aeruginosa with MIC values 9.0, 9.0, and 7.0 μg/mL, respectively, whereas compounds 7c exhibited moderate activities (MIC 11 μg/mL) compared to amoxicillin. On the other hand, P. aeruginosa was resistant to compound 7a. Moreover, compounds 5a, 6, 7a, and 7c displayed strong effectiveness against E. coli (MIC 8.0–9.0 μg/mL), whereas compound 7b displayed moderate action in comparison with the original antibacterial agent (MIC 5.0 μg/mL).

Table 1. Antibacterial Activity (Inhibition Zone and MIC) of Compounds 5a, 6, 7a, 7b, and 7c.

  Samples
  
  (inhibition zone, mm) and MIC (μg/mL)
 reference
Bacteria 5a 6 7a 7b 7c amoxicillin
B. cereus (Gram +ve) 14 (7) 15 (9.0) 14 (10) 17 (8.0) 13 (11) 20 (4.0)
S. aureus (Gram + ve) 16 (8) 19 (9.0) 15 (9.0) 18 (8.0) 15 (9.0) 21 (3.0)
P. aeruginosa (Gram −ve) 12 (7) 15 (9.0)   14 (9.0) 17 (11) 20 (3.0)
E. coli (Gram −ve) 18 (9) 17 (8.0) 18 (8.0) 14 (10) 13 (9.0) 23 (5.0)
Open in a new tab

Antifungal Activity

It is interesting to mention that the results of antifungal screening for the tested compounds revealed promising impacts against all kinds of fungi as indicated in Table 2. From the antifungal data, we found that compounds 5a, 6, 7b, and 7c exhibited intense activities against Geotrichum candidum (MIC 8.0–9.0 μg/mL) relative to the clotrimazole reference drug (MIC 5.0 μg/mL), while G. candidium was resistant to compound 7a. Subsequently, compounds 5a, 6, 7b, and 7c showed good activities against C. albicans, while compound 7a displayed moderate activity (MIC 10.0 μg/mL). In case of T. rubrum, compound 4a represented the best antifungal activity (MIC 7.0 μg/mL) which is almost the same as clotrimazole (MIC 6.0 μg/mL), while compounds 6, 7a, and 7b exhibited the highest inhibition zones (19–21 mm) which are very close to that of the reference drug (25 mm). However, compound 7c exhibited inferior activity (MIC 11 μg/mL) toward T. rubrum. Additionally, compounds 4a, 7a, and 7b revealed strong activities (MIC 9.0 μg/mL) againstA. flavus, while compound 7c displayed moderate activity. At the same time, A. flavus was resistant to the effect of compound 6 compared with clotrimazole (MIC 4.0 μg/mL).

Table 2. Antifungal Activity (Inhibition Zone and MIC) of Compounds 5a, 6, 7a, 7b, and 7ca,b,c.

  Samples
  
  (inhibition zone, mm) and MIC (μg/mL)
 reference
fungi 5a 6 7a 7b 7c clotrimazole
G. candidum 17 (8.0) 15(8.0) - 18(9.0) 19(9.0) 22(5.0)
C. albicans 15 (7.0) 19(9.0) 20(10) 16(8.0) 15(9.0) 26(3.0)
T. rubrum 16 (7.0) 19(10) 19(9.0) 21(10) 16(11) 25(6.0)
A. flavus 16 (9.0) - 18(9.0) 18(9.0) 11(10) 21(4.0)
Open in a new tab
a

Numbers out parentheses reveal the inhibition zone in (mm) of compounds 4a, 6, 7a, 7b, and 7c.

b

Numbers in parentheses illustrate the MIC in (μg mL) of tested compounds.

c

(-), no activity.

Structure–Activity Relationship

Tetrahydroisoquinolines hold a prominent place in organic and medicinal chemistry. Accordingly, we tried to investigate the influence of various chalcone compounds containing the piperidinyl thienotetrahydroisoquinoline moiety on the microbial inhibitory activity. From the data which are recorded in Table 3, we can deduce that the pyrrolyl-acetyl starting material 5a revealed strong antibacterial activity against all tested strains of bacteria. Formation of the chalcone compound 6 increases the antibacterial activity toward E. coli and slightly decreases the effect against B. cereus, S. aureus, and P. aeruginosa. Alternatively, reaction of the pyrrolyl-acetyl 5a with different aldehydes to form the corresponding chalcone compounds 7a, 7b, and 7c strongly affected on the antibacterial activity. Therefore, reaction with benzaldehyde to form the chalcone 7a strongly increases the effect against S. aureus and E. coli with moderate activity against B. cereus as well as no activity against P. aeruginosa. It is noticeable that substitution of the phenyl ring in benzaldehyde by the nitro group (electron withdrawing group EWG) 7c strongly enhances activity against P. aeruginosa, in addition to moderate or good activity against E. coli. However, substitution by the methoxyl group (electron-donating group) 7b increases the activity against S. aureus and E. coli with moderate to good activities against B. cereus and P. aeruginosa.

Table 3. Physical Properties, Analytical, and Spectral Analyses of Compounds 3a–e.

        analytical data (calcd/found)
  
no mp (°C) yield (%) Mol. formula (M.wt) C H N S spectral analyses
3a 148–150 0.65 g (54%) C18H23N3OS (329.46) 65.62, 65.50 7.04, 6.89 12.75, 12.63 9.73, 9.61 FT-IR ν (cm–1): 2952, 2836, 2815 (CH-aliphatic), 2203 (CN), 1739 (C=O). 1H NMR (400 MHz, CDCl3): δ 1.65–1.69 (m, 6H, 3CH2: C3–C5 piperidinyl), 1.81–1.84 (m, 4H, 2CH2: C6, C7 cyclohexeno), 2.29 (s, 3H, COCH3), 2.42–2.50 (m, 2H, CH2: C5 cyclohexeno), 2.82–2.85 (m, 2H, CH2: C8 cyclohexeno), 3.18–3.19 (m, 4H, 2CH2: C2, C6 piperidinyl), 3.94 (s, 2H, CH2CO) ppm. 13C NMR (100 MHz, CDCl3): 21.79 (C6 cyclohexeno), 22.67 (C7 cyclohexeno), 24.44 (C5 cyclohexeno), 26.03 (C4 piperidinyl), 26.65 (C3, C5 piperidinyl), 27.95 (C14, CH3 acetyl), 28.28 (C8 cyclohexeno), 40.11 (C12, SCH2), 50.12 (C2, C6 piperidinyl), 98.62 (C4), 116.11 (C8a), 119.65 (C9), 150.90 (C4a), 155.76 (C3), 162.53 (C1), 203.44 (C13, C=O) ppm
3b 138–140 0.85 g (64%) C19H25N3O2S (359.49) 63.48, 63.36 7.01, 6.89 11.69, 11.57 8.92, 8.80 FT-IR ν (cm–1): 2967–2846 (CH-aliphatic), 2206 (CN), 1741 (C=O, ester). 1H NMR (400 MHz, CDCl3): δ 1.17–1.21 (t, J = 7.10 Hz, 3H, CH3 ester), 1.62–1.65 (m, 6H, 3CH2: C3–C5 piperidinyl), 1.70–1.74 (m, 4H, 2CH2: C6, C7 cyclohexeno), 2.37–2.39 (m, 2H, CH2: C5 cyclohexeno), 2.64–2.66 (m, 2H, CH2: C8 cyclohexeno), 3.17–3.20 (m, 4H, 2CH2: C2, C6 piperidinyl) 4.16–4.21 (q, J = 7.10 Hz, 2H, CH2 ester), 4.25 (s, 2H, CH2, SCH2CO) ppm. 13C NMR (100 MHz, CDCl3): 13.95 (C16, CH3 ethyl ester), 22.17 (C6 cyclohexeno), 22.40 (C7 cyclohexeno), 22.42 (C5 cyclohexeno), 24.60 (C3−C5 piperidinyl), 26.12 (C8 cyclohexeno), 26.74 (C12, CH2 ethyl ester), 51.00 (C2, C6 piperidinyl), 61.20 (C15, SCH2CO), 109.95 (C4), 122.85 (C8a), 136.95 (C9), 144.44 (C4a), 156.36 (C3), 161.36 (C1), 163.12 (C13, CO ester) ppm
3c 170–172 0.70 g (70%) C23H25N3OS (391.53) 70.56, 70.42 6.44, 6.32 10.73, 10.61 8.19, 8.09 FT-IR ν (cm–1): 3056 (CH-aromatic), 2985–2835 (CH-aliphatic), 2208 (CN), 1689 (C=O). 1H NMR (400 MHz, CDCl3): δ 1.27–1.47 (m, 6H, 3CH2: C3–C5 piperidinyl), 1.63–1.66 (m, 2H, CH2: C7 cyclohexeno), 1.67–1.93 (m, 2H, CH2: C6 cyclohexeno), 2.42–2.45 (m, 2H, CH2: C5 cyclohexeno), 2.66–2.83 (m, CH2: C8 cyclohexeno), 2.88–3.00 (m, 4H, 2CH2: C2, C6 piperidinyl), 4.66 (s, 2H, CH2), 7.40–8.18 (m, 5H, ArH) ppm. 13C NMR (100 MHz, CDCl3): 21.81 (C6 cyclohexeno), 22.66 (C7 cyclohexeno), 24.35 (C5 cyclohexeno), 25.87–26.58 (C3−C5 piperidinyl), 28.26 (C8 cyclohexeno), 37.13 (C12, SCH2CO), 49.95 (C2, C6 piperidinyl), 98.58 (C4), 116.17 (C8a), 119.35 (C9), 128.43–133.44 (C1−C6 Ph), 139.97 (C4a), 155.87 (C3), 162.30 (C1), 193.13 (C13, CO) ppm
3d 154–156 0.75 g (63%) C17H22N4OS (330.45) 61.79, 61.67 6.71, 6.60 16.96, 16.85 9.70, 9.60 FT-IR ν (cm–1): 3425, 3187 (NH2 amide), 2935, 2850, 2816 (CH-aliphatic), 2207 (CN), 1680 (CONH2). 1H NMR (400 MHz, CDCl3): δ 1.65–1.69 (m, 6H, 3CH2: C3–C5 piperidinyl), 1.70–1.75 (m, 2H, CH2: C7 cyclohexeno), 1.82–1.85 (m, H, CH2: C6 cyclohexeno), 2.49–2.52 (m, 2H, CH2: C5 cyclohexeno), 2.83–2.85 (m, 2H, CH2: C8 cyclohexeno), 3.24–3.25 (m, 4H, 2CH2: C2, C6 piperidinyl), 3.84 (s, 2H, SCH2CO), 7.27 (s, 2H, NH2) ppm. 13C NMR (100 MHz, CDCl3): 21.75 (C6 cyclohexeno), 22.66 (C7 cyclohexeno), 24.41 (C5 cyclohexeno), 26.05 (C4 piperidinyl), 26.77 (C3, C5 piperidinyl), 28.34 (C8 cyclohexeno), 34.94 (C12, SCH2CO), 50.11 (C2, C6 piperidinyl), 98.72 (C4), 115.99 (C8a), 119.94 (C9), 151.06 (C4a), 155.08 (C3), 162.65 (C1), 171.09 (C13, CONH2) ppm
3e 186–188 0.88 g (59%) C23H26N4OS (406.55) 67.95, 67.83 6.45, 6.35 13.78, 13.66 7.89, 7.77 FT-IR ν (cm–1): 3260 (NH), 3088 (CH-aromatic), 2934, 2848 (CH-aliphatic), 2206 (CN), 1670 (C=O). 1H NMR (400 MHz, CDCl3): δ 1.58–1.62 (m, 6H, 3CH2: C3–C5 piperidinyl), 1.64–1.84 (m, 4H, 2CH2: C6, C7 cyclohexeno), 2.18–2.26 (m, 2H, CH2: C5 cyclohexeno), 2.84–2.87 (m, 2H, CH2: C8 cyclohexeno), 3.10–3.30 (m, 4H, 2CH2: C2, C6 piperidinyl), 3.95 (s, 2H, SCH2CO), 6.61–7.48 (m, 5H, ArH), 8.70 (s, 1H, NH) ppm. 13C NMR (100 MHz, CDCl3): 21.72 (C6 cyclohexeno), 22.60 (C7 cyclohexeno), 24.34 (C5 cyclohexeno), 25.99–26.75 (C3−C5 piperidinyl), 28.39 (C8 cyclohexeno), 34.40 (C12 SCH2), 50.16 (C2, C6 piperidinyl), 98.99 (C4), 115.90 (C8a), 119.89 (C9), 120.29–137.69 (C1−C6 Ph), 151.23 (C4a), 155.11 (C3), 162.66 (C1), 166.53 (C13, CONH) ppm
Open in a new tab

Additionally, the recently synthesized compounds exhibited variable degrees of fungal inhibitory activity. Compound 5a revealed high activity against all genera of fungi, while reaction with DMFDMA to form the chalcone 6 slightly decreases the effect against C. albicans and T. rubrum. Antifungal activity of compound 6 against G. candidium is very close to the effect of 5a, showing inferior activity against A. flavus. Furthermore, reaction of 5a with benzaldehyde to form chalcone 7a slightly decreases the activity against C. albicans and T. rubrum. The effect of chalcone 7a is very similar to 5a against A. flavus with inferior activity versus G. candidium. Substitution of the phenyl ring of benzaldehyde with electron withdrawing group (NO2) 7c or electron donating group (OCH3) 7b strongly enhanced the activity against G. candidium by increasing the activity against C. albicans and T. rubrum. The methoxyl group in compound 7b slightly reduced the efficacy against A. flavus, while substitution by the nitro group did not influence the activity as compared to 7a.

Development of a 2D-QSAR Model

The descriptor reflects the molecular merits. The screening of various significant molecular descriptors from many other ones is an imperative procedure in the QSAR research. The best QSAR model should have appropriate number of descriptors.

graphic file with name ao9b02604_m001.jpg

N and D represent the number of compounds and descriptors, respectively.

In our study, the number of compounds tested for antibacterial and antifungal activity is limited (only five compounds). Therefore, to meet the criteria the QSAR equation will contain only one descriptor.

A simple 2D-QSAR analyses for antibacterial activity and antifungal activities of the prepared derivatives (5a, 6, 7a, 7b, and 7c) was performed using MOE 2019 software.

A set of the synthesized compounds 5a, 6, 7a, 7b, and 7c was used as a training set with their measured MIC against B. cereus and C. albicans for QSAR modeling. MIC values against B. cereus and C. albicans were chosen for QSAR modeling; they were the training set compounds that showed best activity. A database for the training set compounds was established and different molecular 2D descriptors was calculated using MOE 2019 software. Next, the “best multilinear regression” was determined. In our study, PLS regression analysis was used to calculate the relationship between bioactivity and the descriptors. The QSAR model was validated employing leave one-out cross-validation.

2D QSAR Study Results

In the 2D-QSAR equation development for B. cereus, the regression equation indicated that the total hydrophobic vdw surface area (PEOE_VSA_HYD) of the training set compounds has a contribution to the inhibitory activity (eq 1). The correlation coefficient (r2) is 0.81, and the root-mean-square error (RMSE) is 0.61. The predicted values are plotted versus experimental MIC results of the training set compounds against B. cereus, as given in Figure 2.

Best performing QSAR model for the activity against B. cereus
graphic file with name ao9b02604_m002.jpg 1

Figure 2.

Figure 2

Open in a new tab

Predicted vs experimental MIC of the tested compounds against B. cereus. According to eq 1, r2 = 0.818 and RMSE = 0.61.

The total hydrophobic vdw surface area (PEOE_VSA_HYD) of the training set compounds showed also an influence on the inhibitory activity against C. albicans (eq 2). The correlation coefficient (r2) is 0.62, and the root-mean-square error (RMSE) is 0.61. The predicted values are plotted versus experimental MIC results of the training set compounds against B. cereus, as given in Figure 3.

Best performing QSAR model for the activity against C. albicans
graphic file with name ao9b02604_m003.jpg 2

Figure 3.

Figure 3

Open in a new tab

Predicted vs experimental MIC of the tested compounds against C. albicans. According to eq 2, r2 = 0.61 and RMSE = 0.62.

Experimental Section

The required chemicals in this work were purchased from Merck Sigma-Aldrich and Loba chemicals. All melting points were uncorrected and determined on a Fisher–John apparatus. Elemental analyses were performed at the Micro Analytical Center of Chemistry Department, Assiut University, Egypt. The FT-IR spectra were recorded using potassium bromide disks on a FT-IR8201PC Shimadzu. H and C nuclear magnetic resonance (NMR) spectra were recorded on Bruker BioSpin GmbH spectrometers and Varian Mercury VX-300NMR (1H 400 MHz, 13C NMR 100 MHz) in CDCl3 and DMSO-d6 using tetramethylsilane (Me4Si) as the internal standard. Chemical shifts were expressed as ppm. Mass spectra were measured on a Joel-JMS 600 spectrometer at Chemistry Department—Assiut University, Egypt. All reactions were monitored by the thin-layer chromatography technique on silica gel-coated aluminum sheets (Silica gel60 F254, Merck). The amino isothiochromene carbonitrile compound 1 was synthesized according to the literature procedure.38

4-Cyano-1-piperidinyl-5,6,7,8-tetrahydroisoquinoline-3(2H)-thione (2)

A solution of 3-amino-1-thioxo-5,6,7,8-tetrahydro-1H-isothiochromene-4-carbonitrile (1) (5.00 g, 22 mmol) and piperidine (7.00 mL, 82 mmol) was heated on a steam bath at 100 °C for 6 h under solvent-free conditions. After the reaction was completed, a solution of absolute ethanol (15 mL) and acetic acid (6 mL) was appended, and then, reflux was resumed for additional 10 min and was left to cool. The precipitated solid which was formed on cooling was collected and recrystallized from the ethanol/dioxane mixture (1:1) as red crystals in 80% (4.00 g) yield. mp 208–210 °C Anal. Calcd for C15H19N3S (273.13): C, 65.90; H, 7.01; N, 15.37; S, 11.73%. Found: C, 65.78; H, 6.91; N, 15.27; S, 11.61%. FT-IR ν (cm–1): 3440 (NH), 2930, 2853 (CH-aliphatic), 2207 (CN), 1560 (C=S). 1H NMR (400 MHz, CDCl3): δ 1.39–1.54 (m, 6H, 3CH2: C3–C5 piperidinyl), 1.57–1.70 (m, 2H, CH2: C7 cyclohexeno), 1.75–1.95 (m, 2H, CH2: C6 cyclohexeno), 2.34–2.52 (m, 2H, CH2: C8 cyclohexeno), 2.71–2.87 (m, 2H, CH2: C5 cyclohexeno), 3.03–3.19 (m, 4H, 2CH2: C2, C6 piperidinyl), 12.09 (s, 1H, NH) ppm. 13C NMR (100 MHz, CDCl3): 21.80 (C4 piperidinyl), 22.75 (C8 cyclohexeno), 24.54 (C3, C5 piperidinyl), 25.86 (C7 cyclohexeno), 26.97 (C6 cyclohexeno), 28.27 (C5 cyclohexeno), 49.78 (C2, C6 piperdinyl), 97.85 (C8a), 116.06 (C4), 120.12 (C9), 150.51 (C1), 155.35 (C3), 162.07 (C4a) ppm.

3-Substituted Mercapto-1-(piperdinyl)-5,6,7,8-tetrahydroisoquinoline-4-carbonitrile (3a–e)

General Procedure

The thione 2 (1.00 g, 3.60 mmol) and the α-halo alkylating agent (3.60 mmol) in ethanol (10 mL) and fused sodium acetate (0.50 g, 6.00 mmol) were refluxed for 2 h. The product that formed on cooling was filtered, washed with water, dried, and recrystallized from ethanol. The physical properties and elemental and spectral analyses of compounds 3a–e are given in Table 3.

1-Amino-2-substituted-5-(piperidinyl)-6,7,8,9-tetrahydrothieno[2,3-c]isoquinoline (4a–e)

Method a

To a solution of the proper S-alkylated products 3a–e (0.01 mol) in absolute ethanol (15 mL), sodium ethoxide solution (1.50 mL) (prepared from 0.50 g of the finely divided clean sodium metal in 20 mL absolute ethanol) was added; then, the reaction mixture was heated under reflux for 10 min and left to cool. The precipitated solids, while hot during reflux, were collected and recrystallized from ethanol.

Method b

A solution of 2 (2.73 g, 0.01 mol) and the alkylating agent (0.01 mol) in ethanol (15 mL) and anhydrous potassium carbonate (3.00 g, 0.02 mol) in ethanol (15 mL) was refluxed for 3 h; then, the mixture was allowed to cool. The solid products were collected, washed with water, dried, and recrystallized from the ethanol/dioxane mixture (1:1). The physical constants, elemental analyses, and spectral data of compounds 4a–e are listed in Table 4.

Table 4. Physical Properties and Analytical and Spectral Data of Compounds 4a–e.
        analytical data (calcd/found)
  
no mp (°C) yield (%) mol. formula (M.wt) C H N S spectral analyses
4a 202–204 0.50 g (76%) C18H23N3OS (329.46) 65.62, 65.50 7.04, 6.92 12.75, 12.63 9.73, 9.61 FT-IR ν (cm–1): 3449, 3271 (NH2) 2934, 2848 (CH-aliphatic), 1589 (C=O). 1H NMR (400 MHz, CDCl3): δ 1.63–1.70 (m, 6H, 3CH2: C3–C5 piperidinyl), 1.72–1.93 (m, 4H, 2CH2: C7, C8 cyclohexeno), 2.39 (s, 3H, COCH3), 2.59–2.67 (m, 2H, CH2: C6 cyclohexeno), 3.12–3.17 (m, 2H, CH2: C9 cyclohexeno), 3.18–3.31 (m, 4H, 2CH2: C2, C6 piperidinyl), 7.20 (s, 2H, NH2) ppm. 13C NMR (100 MHz, CDCl3): 22.22 (C7 cyclohexeno), 22.36 (C8 cyclohexeno), 24.59 (C4 piperidinyl), 26.10 (C3, C5 piperidinyl), 26.76 (C12 COCH3), 27.31 (C6 cyclohexeno), 29.01 (C9 cyclohexeno), 50.84 (C2, C6 piperidinyl), 104.70 (C5a), 118.44 (C9b), 121.85 (C1), 144.45 (C9a), 150.97 (C2), 158.58 (C3a), 163.89 (C5), 192.32 (C11, CO) ppm
4b 140–142 0.40 g (80%) C19H25N3O2S (359.49) 63.48, 63.36 7.01, 6.89 11.69, 11.57 8.92, 8.80 FT-IR ν (cm–1): 3493, 3337 (NH2), 2986–2818 (CH-aliphatic), 1657 (C=O ester). 1H NMR (400 MHz, CDCl3): δ 1.23–1.26 (t, J = 6.80 Hz, 3H, CH3 ester), 1.42–1.63 (m, 6H, 3CH2: C3–C5 piperidinyl), 1.65–1.93 (m, 4H, 2CH2: C7, C8 cyclohexeno), 2.32–2.44 (m, 2H, CH2: C6 cyclohexeno), 2.72–2.86 (m, 2H, CH2: C9 cyclohexeno), 3.00–3.15 (m, 4H, 2CH2: C2, C6 piperidinyl), 3.70–3.75 (q, J = 6.80 Hz, 2H, CH2 ester), 7.00 (s, 2H, NH2) ppm. 13C NMR (100 MHz, CDCl3): 21.80 (C14, CH3 ester), 22.75 (C7 cyclohexeno), 24.54 (C8 cyclohexeno), 25.86 (C3−C5 piperidinyl), 26.98 (C6 cyclohexeno), 28.28 (C9 cyclohexeno), 49.78 (C2, C6 piperidinyl), 97.85 (C13, OCH2 ester), 116.06 (C5a, C2), 120.12 (C9b), 150.51 (C1, C9a), 155.36 (C3a, C5), 162.07 (C11, CO) ppm. EI–MS (m/z): 359.23 [M+, 28.00%], 84.15 [M+ – piperidinyl, 100%]
4c 210–212 0.75 g (75%) C23H25N3OS (391.53) 70.56, 70.44 6.44, 6.33 10.73, 10.63 8.19, 8.07 FT-IR ν (cm–1): 3432, 3236 (NH2), 3010 (CH-aromatic), 2977, 2932, 2830 (CH-aliphatic), 1582 (C=O). 1H NMR (400 MHz, CDCl3): δ 1.62–1.69 (m, 6H, 3CH2: C3–C5 piperidinyl), 1.70–1.73 (m, 2H, CH2: C7 cyclohexeno), 1.74–1.94 (m, 2H, CH2: C8 cyclohexeno), 2.46–2.67 (m, 2H, CH2: C6 cyclohexeno), 3.17–3.19 (m, 2H, CH2: C9 cyclohexeno), 3.24–3.28 (m, 4H, 2CH2: C2, C6 piperidinyl), 7.64–7.27 (m, 5H, ArH), 7.83 (s, 2H, NH2) ppm. 13C NMR (100 MHz, CDCl3): 22.23 (C7 cyclohexeno), 22.39 (C8 cyclohexeno), 24.58 (C4 piperidinyl), 26.08 (C3, C5 piperidinyl), 26.87 (C6 cyclohexeno), 27.51 (C9 cyclohexeno), 50.77 (C2, C6 piperidinyl), 103.61 (C2), 117.93 (C5a), 121.71 (C9b), 127.84 (C3, C5 Ph), 130.62 (C2, C6 Ph), 141.51 (C9a), 144.48 (C1), 153.34 (C1 Ph), 160.45 (C3a), 163.93 (C5), 189.75 (C11, CO) ppm.
4d 240–242 0.75 g (75%) C17H22N4OS (330.45) 61.79, 61.67 6.71, 6.60 16.96, 16.85 9.70, 9.60 FT-IR ν (cm–1): 3498, 3477 (NH2 amide), 3307, 3248, 3124 (NH2 amine), 2924, 2853, 2822 (CH-aliphatic), 1643 (C=O). 1H NMR (400 MHz, CDCl3): δ 1.44–1.65 (m, 6H, 3CH2: C3–C5 piperidinyl), 1.80–1.83 (m, 2H, CH2: C7 cyclohexeno), 2.50–2.51 (m, 2H, CH2: C8 cyclohexeno), 2.61–2.63 (m, 2H, CH2: C6 cyclohexeno), 3.04, 3.10 (m, 2H, CH2: C9 cyclohexeno), 3.24–3.30 (m, 4H, 4H, 2CH2: C2, C6 piperidinyl), 6.83 (s, 2H, NH2), 6.95 (s, 2H, NH2) ppm. 13C NMR (100 MHz, CDCl3): 22.25 (C7 cyclohexeno), 22.30 (C8 cyclohexeno), 24.58 (C4 piperidinyl), 26.14 (C3, C5 piperidinyl), 26.37 (C6 cyclohexeno), 26.84 (C9 cyclohexeno), 51.04 (C2, C6 piperidinyl), 95.81 (C5a), 120.27 (C9b), 121.56 (C2), 144.93 (C9a), 149.29 (C1), 155.72 (C3a), 162.66 (C5), 168.02 (C11, CO) ppm
4e 206–208 0.88 g (88%) C23H26N4OS (406.55) 67.95, 67.83 6.45, 6.35 13.78, 13.66 7.89, 7.77 FT-IR ν (cm–1): 3501, 3405 (NH2), 3320 (NH), 3080 (CH-aromatic), 2941, 2850, 2816 (CH-aliphatic), 1635 (CONH). 1H NMR (400 MHz, DMSO-d6): δ 1.46–1.65 (m, 6H, 3CH2: C3–C5 piperidinyl), 1.80–1.83 (m, 2H, CH2: C7 cyclohexeno), 2.49–2.52 (m, 2H, CH2: C8, C6 cyclohexeno), 2.55–2.64 (m, 2H, CH2: C6 cyclohexeno), 2.90–3.15 (m, 2H, CH2: C9 cyclohexeno), 3.08–3.10 (m, 4H, 2CH2: C2 C6 piperidinyl), 7.00 (s, 2H, NH2), 7.30–7.80 (m, 5H, ArH), 9.19 (s, 1H, NH) ppm. 13C NMR (100 MHz, DMSO-d6): 22.25 (C7 cyclohexeno), 22.28 (C8 cyclohexeno), 24.58 (C4 piperidinyl), 26.13 (C3, C5 piperidinyl), 26.49 (C6 cyclohexeno), 27.00 (C9 cyclohexeno), 50.99 (C2, C6 piperidinyl), 95.22 (C5a), 119.91 (C2, C6 Ph), 121.70 (C9b), 123.70 (C4 Ph), 128.81 (C3, C5 Ph, C2), 139.49 (C9a), 145.12 (C1), 150.99 (C1 Ph), 156.23 (C3a), 162.95 (C5), 164.94 (C11, CONH) ppm
Open in a new tab

1-(5-(Piperidinyl)-1-(1H-pyrrolyl)-6,7,8,9-tetrahydrothieno[2,3-c]isoquinolin-2-yl)ethan-1-one (5a)

The amino-acetyl 4a (0.50 g, 1.50 mmol) and 2,5-dimethyoxytetrahydrofuran (0.20 mL, 1.50 mmol) in acetic acid (3 mL) was gently refluxed for 1 h. The solid precipitate formed on cooling was filtered, dried, and recrystallized from ethanol as white crystals in 70% (0.40 g) yield, mp 160–162 °C. Anal. Calcd for C22H25N3OS (379.52): C, 69.62; H, 6.64; N, 11.07; S, 8.45%. Found: C, 69.50; H, 6.52; N, 10.95; S, 8.35%. FT-IR ν (cm–1): 3108 (CH-pyrrolyl), 2936, 2849 (CH-aliphatic), 1651 (C=O acetyl), 1560 (CN). 1H NMR (400 MHz, CDCl3): δ 1.53–1.65 (m, 6H, 3CH2: C3–C5 piperidinyl), 1.70–1.82 (m, 4H, 2CH2: C7, C8 cyclohexeno), 1.95 (s, 3H, CH3 acetyl), 2.24–2.31 (m, 2H, CH2: C6 cyclohexeno), 2.54–2.65 (m, 2H, CH2: C9 cyclohexeno), 3.08–3.21 (m, 4H, 2CH2: C2, C6 piperidinyl), 6.37–6.47 (m, 2H, C3–C4 pyrrolyl), 6.70–6.85 (m, 2H, C2, C5 pyrrolyl) ppm. 13C NMR (100 MHz, CDCl3): 22.11 (C8 cyclohexeno), 22.16 (C7 cyclohexeno), 22.40 (C4 piperidinyl), 24.58 (C11, CH3 acetyl), 25.83 (C3, C5 piperidinyl), 26.09 (C6 cyclohexeno), 26.85 (C9 cyclohexeno), 50.94 (C2, C6 piperidinyl), 110.32 (C3, C4 pyrrolyl), 123.11 (C2, C5 pyrrolyl), 123.78 (C5a), 123.92 (C9b), 135.22 (C9a), 136.04 (C2), 144.67 (C1), 157.30 (C3a), 163.22 (C5), 192.12 (C10, CO) ppm. EI–MS (m/z): 379.23 [M+, 68%], 350.20 [M+ – CHO, 21%], 323.20 [M+ – pyrrolyl-CH4, 21%], 296.17 [M+ – C4H4N–OCH3, 2%], 84.15 [M+ – piperidinyl, 100%].

Ethyl 5-(Piperidinyl)-1-(1H-pyrrolyl)-6,7,8,9-tetrahydrothieno[2,3-c]isoquinoline-2-carboxylate (5b)

The amino ester 4b (0.50 g, 1.40 mmol) and 2,5-dimethyoxytetrahydrofuran (0.20 mL, 1.50 mmol) in acetic acid (4 mL) was refluxed for 1 h. The solid precipitated upon cooling was collected and recrystallized from ethanol as white needles in 71% (0.40 g) yield, mp 138–140 °C. Anal. Calcd for C23H27N3O2S (409.55): C, 67.45; H, 6.65; N, 10.26; S, 7.83%. Found: C, 67.33; H, 6.55; N, 10.16; S, 7.71%. FT-IR ν (cm–1): 3118 (CH-pyrrolyl), 2993–2862 (CH-aliphatic), 1690 (C=O ester), 1563 (C=N). 1H NMR (400 MHz, CDCl3): δ 1.34–1.38 (t, J = 7.10 Hz, 3H, CH3 ester), 1.62–1.69 (m, 6H, 3CH2: C3–C5 piperidinyl), 1.70–1.72 (m, 2H, CH2: C7 cyclohexeno), 1.88–1.98 (m, 2H, CH2: C8 cyclohexeno), 2.63–2.66 (m, 2H, CH2: C6 cyclohexeno), 3.13–3.16 (m, 2H, CH2: C9 cyclohexeno), 3.20–3.23 (m, 4H, 2CH2: C2, C6 piperidinyl), 4.28–4.33 (q, J = 7.10 Hz, 2H, CH2 ester), 6.20–6.33 (m, 2H, C3, C4 pyrrolyl), 7.15–7.46 (m, 2H, C2, C5 pyrrolyl) ppm. 13C NMR (100 MHz, CDCl3): 14.55 (C13, CH3 ester), 22.25 (C7 cyclohexeno), 22.41 (C8 cyclohexeno), 24.62 (C4 piperidinyl), 26.14 (C3, C5 piperidinyl), 26.61 (C6 cyclohexeno), 27.71 (C9 cyclohexeno), 50.91 (C2, C6 piperidinyl), 60.06 (C12, CH2 ester), 94.59 (C3, C4 pyrrolyl), 118.91 (C5a), 121.65 (C2, C5 pyrrolyl), 121.65 (C9b), 143.60 (C2, C9a), 158.35 (C1), 163.34 (C3a, C5), 166.08 (C10, CO ester) ppm.

3-(Dimethylamino)-1-(5-(piperidinyl)-1-(1H-pyrrolyl)-6,7,8,9-tetrahydrothieno[2,3-c]isoquinolin-2-yl)prop-2-enone (6)

The pyrrolyl acetyl 5a (2.00 g, 5.00 mmol) and DMFDMA (10 mL) was heated under reflux for 6 h. The solid precipitated, which separated out during reflux was filtered, dried, and recrystallized from ethanol as yellow crystals in 57% (1.30 g) yield, mp 204–206 °C. Anal. Calcd for C25H30N4OS (434.62): C, 69.09; H, 6.96; N, 12.89; S, 7.38%. Found: C, 68.97; H, 6.84; N, 12.77; S, 7.26%. FT-IR ν (cm–1): 3104 (CH-pyrrolyl), 2925, 2851 (CH-aliphatic), 1632 (C=O), 1560 (C=N). 1H NMR (400 MHz, CDCl3): δ 1.43–1.65 (m, 6H, 3CH2: C3–C5 piperidinyl), 1.70–1.82 (m, 2H, CH2: C7 cyclohexeno), 1.95 (s, 6H, 2CH3), 2.36–2.39 (m, 2H, CH2: C8 cyclohexeno), 2.55–2.65 (m, 2H, CH2: C6 cyclohexeno), 3.03–3.14 (m, 2H, CH2: C9 cyclohexeno), 3.16–3.21 (m, 4H, 2CH2: C2, C6 piperidinyl), 4.27–4.30 (d, J = 12.20 Hz, 1H, C11, CH=CH benzylidene), 6.33–6.38 (m, 2H, C3, C5 pyrrolyl), 6.76–6.79 (m, 2H, C2, C4 pyrrolyl), 7.67–7.70 (d, J = 12.20 Hz, 1H, C12, CH=CH benzylidene) ppm. 13C NMR (100 MHz, CDCl3): 22.34 (C7 cyclohexeno), 22.41 (C8 cyclohexeno), 24.59 (C4 piperidinyl), 25.84 (C3, C5 piperidinyl), 26.86 (C6 cyclohexeno), 36.96 (C9 cyclohexeno), 50.94 (C14, C15 2CH3), 51.11 (C2, C6 piperidinyl), 92.24 (C11, CH=CH benzylidene), 109.55 (C3, C4 pyrrolyl), 123.12 (C5a), 130.88 (C2, C5 pyrrolyl), 135.24 (C9b), 140.22 (C9a), 143.76 (C2), 144.69 (C12, CH=CH benzylidene), 154.02 (C1), 163.23 (C3a), 180.33 (C5), 192.42 (C10, CO) ppm. EI–MS (m/z): 467.00 [M+, 12%], 84.15 [M+ – piperidinyl, 27%].

3-Arylidene-1-(5-(piperidinyl)-1-(1H-pyrrolyl)-6,7,8,9-tetrahydrothieno[2,3-c]isoquinolin-2-yl)prop-2-enone (7a–c)

General Procedure

A mixture of the pyrrolyl-acetyl 5a (0.50 g, 1.30 mmol) and the aromatic aldehyde (0.30 mL, 2.80 mmol) in ethanolic sodium hydroxide solution (1.00 g in 10 mL ethanol) was refluxed for 30 min. The solid precipitate that formed during reflux was filtered, dried, and recrystallized from ethanol.

3-Phenyl-1-(5-(piperidinyl)-1-(1H-pyrrolyl)-6,7,8,9-tetrahydrothieno[2,3-c]isoquinolin-2-yl)prop-2-enone (7a)

Benzaldehyde 7a, (EtOH), 60% (0.37 g) yield, yellow crystals, mp 208–210 °C. Anal. Calcd for C29H29N3OS (467.63): C, 74.49; H, 6.25; N, 8.99; S, 6.86%. Found: C, 74, 39; H, 6.13; N, 8.87; S, 6.74%. FT-IR ν (cm–1): 3125 (CH-pyrrolyl), 3050 (CH-aromatic), 2933, 2853 (CH-aliphatic), 1638 (C=O). 1H NMR (400 MHz, CDCl3): δ 1.41–1.66 (m, 6H, 3CH2: C3–C5 piperidinyl), 1.71–1.84 (m, 4H, 2CH2: C7, C8 cyclohexeno), 2.27–2.40 (m, 2H, CH2: C6 cyclohexeno), 2.56–2.66 (m, 2H, CH2: C9 cyclohexeno), 3.21–3.24 (m, 4H, 2CH2: C2, C6 piperidinyl), 5.68–5.71 (d, J = 15.20 Hz, 1H, C11 CH=CH benzylidene), 6.50–6.51 (m, 2H, C3, C4 pyrrolyl), 6.89–6.90 (m, 2H, C2, C5 pyrrolyl), 7.33–7.45 (m, 5H, ArH), 7.69, 7.73 (d, J = 15.23 Hz, 1H, C12 CH=CH benzylidene) ppm. 13C NMR (100 MHz, CDCl3): 22.21 (C7 cyclohexeno), 22.43 (C8 cyclohexeno), 22.67 (C4 piperidinyl), 24.60 (C3, C5 piperidinyl), 26.11 (C6 cyclohexeno), 26.91 (C9 cyclohexeno), 50.95 (C2, C6 piperidinyl), 110.37 (C3, C4 pyrrolyl), 121.79 (C5a), 123.74 (C2, C5 pyrrolyl), 123.83 (C11, CH=CH benzylidene), 124.25 (C9b), 128.65–130.27 (C3–C6 Ph), 134.47 (C9a), 135.07 (C1 Ph), 137.21 (C2), 144.06 (C12, CH=CH benzylidene), 144.99 (C1), 157.76 (C3a), 163.13 (C5), 182.09 (C10, CO) ppm. EI–MS (m/z): 467.34 [M+, 15%], 84.15 [M+ – piperidinyl, 100%].

3-(4-Methoxylphenyl)-1-(5-(piperidinyl)-1-(1H-pyrrolyl)-6,7,8,9-tetrahydrothieno[2,3-c]isoquinolin-2-yl)prop-2-enone (7b)

p-Anisaldehyde 7b, (EtOH), in 60% (0.39 g) yield as yellow crystals, mp 230–232 °C. Anal. Calcd for C30H31N3O2S (497.66): C, 72.41; H, 6.28; N, 8.44; S, 6.44%. Found: C, 72.29; H, 6.16; N, 8.32; S, 6.87%. FT-IR ν (cm–1): 3109 (CH-pyrrolyl), 3055 (CH-aromatic), 2926, 2849 (CH-aliphatic), 1648 (C=O), 1560 (C=N). 1H NMR (400 MHz, CDCl3): δ 1.61–1.69 (m, 6H, 3CH2: C3–C5 piperidinyl), 1.70–1.80 (m, 4H, 2CH2: C7, C8 cyclohexeno), 1.95 (s, 3H, OCH3), 2.30–2.33 (m, 2H, CH2: C6 cyclohexeno), 2.63–2.65 (m, 2H, CH2: C9 cyclohexeno), 3.19–3.21 (m, 4H, 2CH2: C2, C6 piperidinyl), 5.56–5.60 (d, J = 15.42 Hz, H, C11, CH=CH benzylidene), 6.35–6.38 (m, 2H, C3, C4 pyrrolyl), 6.49–6.50 (m, 2H, C2, C5 pyrrolyl), 6.08–7.33 (2d, J = 15.42 Hz, 4H, ArH p-sub), 7.67–7.69 (d, J = 15.42 Hz, 1H, C12, CH=CH benzylidene) ppm. 13C NMR (100 MHz, CDCl3): 22.15 (C7 cyclohexeno), 22.41 (C8 cyclohexeno), 22.79 (C4 piperidinyl), 24.58 (C3, C5 piperidinyl), 26.08 (C6 cyclohexeno), 27.02 (C9 cyclohexeno), 50.89 (C2, C6 piperidinyl), 67.09 (C14 OCH3), 110.90 (C3, C4 pyrrolyl), 123.64 (C5a, C3, C5 Ph), 123.90 (C2, C5 pyrrolyl), 124.43 (C11, CH=CH benzylidene), 125.88 (C9b), 129.09–135.14 (C1, C2, C6 Ph), 136.44 (C9a), 140.47 (C2), 141.35 (C12, CH=CH benzylidene), 144.66 (C1), 148.22 (C3a), 158.20 (C4 Ph), 163.31 (C5), 182.43 (C10, CO) ppm.

3-(4-Nitrophenyl)-1-(5-(piperidinyl)-1-(1H-pyrrolyl)-6,7,8,9-tetrahydrothieno[2,3-c]isoquinolin-2-yl)prop-2-enone (7c)

p-Nitrobenzaldhyde 7c, (EtOH), in 59% (0.22 g) yield as orange crystals, mp 210–212 °C. Anal. Calcd for C29H28N4O3S (512.63): C, 67.95; H, 5.51; N, 10.93; S, 6.25%. Found: C, 67.83; H, 5.39; N, 10.81; S, 6.13%. FT-IR ν (cm–1): 3120 (CH-pyrrolyl), 3010 (CH-aromatic), 2932–2848 (CH-aliphatic), 1640 (C=O), 1599 (C=N). 1H NMR (400 MHz, CDCl3): δ 1.58–1.67 (m, 6H, 3CH2: C3–C5 piperidinyl), 1.68–1.86 (m, 4H, 2CH2: C7, C8 cyclohexeno), 2.23–2.40 (m, 2H, CH2: C6 cyclohexeno), 2.49–2.66 (m, 2H, CH2: C9 cyclohexeno), 3.23–3.26 (m, 4H, 2CH2: C2, C6 piperidinyl), 5.66–5.70 (d, J = 7.40 Hz, 1H, CH=CH, C11 benzylidene), 6.51–6.52 (m, 2H, C3, C4 pyrrolyl), 6.91–6.92 (m, 2H, C2, C5 pyrrolyl), 7.32–7.45 (m, 3H, ArH), 7.65–7.67 (d, J = 7.40 Hz, 1H, CH=CH, C12 benzylidene), 8.12–8.19 (m, 2H, ArH) ppm. 13C NMR (100 MHz, CDCl3): 22.10 (C7 cyclohexeno), 22.40 (C8 cyclohexeno), 24.56 (C4 piperidinyl), 25.83 (C3, C5 piperidinyl), 26.10 (C6 cyclohexeno), 26.85 (C9 cyclohexeno), 50.93 (C2, C6 piperidinyl), 110.23 (C3, C4 pyrrolyl), 110.32 (C5a), 114.14 (C2, C5 pyrrolyl), 123.11 (C11, CH=CH, benzylidene), 123.77 (C9b), 123.91–124.26 (C2, C3, C5, C6 Ph), 130.52 (C9a), 129.09 (C1 Ph), 157.31 (C2), 144.00 (C12, CH=CH, benzylidene), 144.66 (C4 Ph), 144.66 (C1), 161.24 (C3a), 163.22 (C5), 192.11 (C10, CO) ppm.

2-(1,5-Diphenyl-4,5-dihydro-1H-pyrazol-3-yl)-5-(piperidinyl)-1-(1H-pyrrolyl)-6,7,8,9-tetrahydrothieno[2,3-c]isoquinoline (8)

A suspension of the chalcone 7a (0.50 g, 1.00 mmol) and phenyl hydrazine (0.15 mL, 1.40 mol) in ethanol (10 mL) and acetic acid (10 mL) was heated under reflux for 6 h. The solid product that separated out throughout reflux was collected and recrystallized from ethanol as pale greenish yellow crystals in 37% (0.22 g) yield, mp 192–194 °C. Anal. Calcd for C35H35N5S (557.76): C, 75.37; H, 6.33; N, 12.56; S, 5.75%. Found: C, 75.26; H, 6.23; N, 12.41; S, 5.57%. FT-IR ν (cm–1): 3119 (CH-pyrrolyl), 3037 (CH-aromatic), 2930, 2849 (CH-aliphatic), 1636 (C=N). 1H NMR (400 MHz, CDCl3): δ 1.51–1.64 (m, 6H, 3CH2: C3–C5 piperidinyl), 1.65–1.84 (m, 4H, 2CH2: C7, C8 cyclohexeno), 2.09–2.66 (m, 4H, 2CH2: C6, C9 cyclohexeno), 3.05–3.23 (m, 4H, 2CH2: C2, C6 piperidinyl), 3.63–3.70 (d, J = 14.20 Hz, 2H, CH2: C4 pyrazole), 5.03–5.18 (t, J = 14.20 Hz, 1H, CHPh), 6.17–6.35 (m, 2H, C3, C4 pyrrolyl), 6.69–7.14 (m, 5H, ArH), 7.15–7.24 (m, 2H, C2, C5 pyrrolyl), 7.29–7.40 (m, 4H, ArH′), 7.69–7.72 (m, 1H, ArH′) ppm. 13C NMR (100 MHz, CDCl3): 21.87 (C7 cyclohexeno), 22.03 (C8 cyclohexeno),26.68 (C4 piperidinyl), 24.49 (C3, C5 piperidinyl), 26.08 (C6 cyclohexeno), 29.70 (C9 cyclohexeno), 51.05 (C4, CH2 pyrazolyl), 58.78 (C2, C6 piperidinyl), 64.81 (C5, CHPh pyrazolyl), 109.66 (C3, C4 pyrrolyl), 110.40 (C5a), 110.63 (C2, C6 Ph), 113.46 (C2, C5 pyrrolyl), 114.00 (C4 Ph), 114.21 (C9b), 124.26 (C2), 125.32 (C4 Ph′), 125.90 (C2, C6 Ph′), 127.56 (C3, C5 Ph′), 128.56 (C3, C5 Ph), 128.65 (C9a), 128.76 (C1 Ph′), 128.88 (C1 Ph), 129.05 (C1), 129.34 (C3a), 130.28 (C3 pyrazolyl), 135.04 (C5) ppm.

5-Phenyl-3-(5-(piperidinyl)-1-(1H-pyrrolyl)-6,7,8,9-tetrahydrothieno[2,3-c]isoquinolin-2-yl)-4,5-dihydroisoxazole (9)

A mixture of chalcone (0.50 g, 1.00 mmol) and hydroxylamine hydrochloride (0.25 g, 3.60 mmol) in ethanol (10 mL) and fused sodium acetate (0.30 g, 3.40 mmol) was heated under reflux for 6 h. The solid product which formed during reflux was collected filtered, dried, and recrystallized from ethanol as pale yellow crystals in 59% (0.30 g) yield, mp 178–180 °C. Anal. Calcd for C29H30N4OS (482.65): C, 72.17; H, 6.27; N, 11.61; S, 6.64%. Found: C, 72.05; H, 6.17; N, 11.49; S, 6.52%. FT-IR ν (cm–1): 3103 (CH-pyrrolyl), 3010 (CH-aromatic), 2932, 2849 (CH-aliphatic), 1636 (C=N). 1H NMR (400 MHz, CDCl3): δ 1.43–1.64 (m, 6H, 3CH2: C3–C5 piperidinyl), 1.71–1.93 (m, 4H, 2CH2: C7, C8 cyclohexeno), 2.22–2.28 (m, 2H, CH2: C6 cyclohexeno), 2.62–2.67 (m, 2H, CH2: C9 cyclohexeno), 2.90–2.97 (d, J = 8.60 Hz, 2H, CH2 isoxazole), 3.14–3.23 (m, 4H, 2CH2: C2, C6 piperidinyl), 5.49, 5.72 (t, J = 8.60 Hz, 1H, CH isoxazole), 6.24–6.50 (m, 2H, C3, C4 pyrrolyl), 6.63–6.72 (m, 2H, C2, C5 pyrrolyl), 6.90–7.36 (m, 5H, ArH) ppm. 13C NMR (100 MHz, CDCl3): 22.22 (C7 cyclohexeno), 22.45 (C8 cyclohexeno), 24.60 (C4 piperidinyl), 26.17 (C3, C5 piperidinyl), 26.60 (C6 cyclohexeno), 29.70 (C9 cyclohexeno), 39.92 (C4, CH2 isoxazole), 51.11 (C2, C6 piperidinyl), 83.56 (C5, CH isoxazole), 109.85 (C3, C4 pyrrolyl), 109.90 (C5a), 110.37 (C2, C5 pyrrolyl), 123.35 (C9b), 123.93 (C2), 124.15–128.84 (C2–C6 Ph), 128.65 (C9a), 128.76 (C1 Ph), 140.17 (C1), 142.96 (C3a), 151.99 (C5), 162.18 (C3 isoxazole) ppm.

5-(Piperidinyl)-1-(1H-pyrrolyl)-6,7,8,9-tetrahydrothieno[2,3-c]isoquinoline-2-carbohydrazide (10)

A solution of the pyrrolyl ester 5b (1.00 g, 2.00 mmol) and hydrazine hydrate (1.00 mL, 0.02 mol) in ethanol (5 mL) was heated under reflux for 7 h. The precipitated solid which separated out during reflux was collected and recrystallized from ethanol as white crystals in 82% (0.85 g) yield, mp 190–192 °C. Anal. Calcd for C21H25N5OS (395.53): C, 63.77; H, 6.37; N, 17.71; S, 8.11%. Found: C, 62.99; H, 6.32; N, 17.45; S, 8.02%. FT-IR ν (cm–1): 3396, 3323, 3300 (NH, NH2), 3121 (CH-pyrrolyl), 2926, 2850 (CH-aliphatic), 1660 (C=O hydrazide), 1562 (C=N). 1H NMR (400 MHz, CDCl3): δ 1.62–1.65 (m, 6H, 3CH2: C3–C5 piperidinyl), 1.70–1.71 (m, 4H, 2CH2: C7, C8 cyclohexeno), 2.32–2.34 (m, 2H, CH2: C6 cyclohexeno), 2.64–2.65 (m, 2H, CH2: C9 cyclohexeno), 3.16–3.19 (m, 4 H, 2CH2: C2, C6 piperidinyl), 3.89 (s, 2H, NH2), 6.26 (s, 1H, NH), 6.46–6.47 (m, 2H, C3, C4 pyrrolyl), 6.77–6.78 (m, 2H, C2, C5 pyrrolyl) ppm. 13C NMR (100 MHz, CDCL3): 22.13 (C7 cyclohexeno), 22.43 (C8 cyclohexeno), 22.48 (C4 piperidinyl), 24.58 (C3, C5 piperidinyl), 26.66 (C6 cyclohexeno), 29.70 (C9 cyclohexeno), 51.03 (C2, C6 piperidinyl), 111.47 (C3, C4 pyrrolyl), 122.47 (C5a), 122.85 (C2, C5 pyrrolyl), 123.41 (C9b), 123.85 (C9a), 129.43 (C2), 131.03 (C1), 143.66 (C3a), 156.12 (C10, C=O), 162.70 (C5) ppm.

N′-(4-Oxo-2-pentylidene)-5-(piperidinyl)-1-(1H-pyrrolyl)-6,7,8,9-tetrahydrothieno[2,3-c]isoquinoline-2-carbohydrazide (11)

A mixture of the carbohydrazide 10 (1.00 g, 2.40 mmol) and acetyl acetone (0.40 mL, 4.00 mmol) in ethanol (20 mL) was refluxed for 1 h. The solid product which formed on hot during reflux was filtered, dried, and recrystallized from ethanol as white crystals in 33% (0.40 g) yield, mp 165–167 °C. Anal. Calcd for C26H31N5O2S (477.63) C, 65.38; H, 6.54; N, 14.66; S, 6.71%. Found: C, 65.26; H, 6.42; N, 14.54; S, 6.59%. FT-IR: ν (cm–1): 3358 (NH), 3100 (CH-pyrrolyl), 2931, 2850 (CH-aliphatic), 1643 (COCH3), 1627 (CONH), 1564 (C=N). 1H NMR (400 MHz, CDCl3): δ 1.25 (s, 3H, N=CCH3), 1.59 (s, 3H, COCH3), 1.61–1.65 (m, 6H, 3CH2: C3–C5 piperidinyl), 1.70–1.72 (m, 4H, 2CH2: C7, C8 cyclohexeno), 2.20–2.23 (m, 2H, CH2: C9 cyclohexeno), 2.63–2.65 (m, 2H, CH2: C6 cyclohexeno), 3.16–3.19 (m, 4H, 2CH2: C2, C6 piperidinyl), 3.35 (s, 2H, CH2CO), 6.47–6.48 (m, 2H, C3, C4 pyrrolyl), 6.85–6.89 (m, 2H, C2, C5 pyrrolyl), 8.18 (s, 1H, NH) ppm. 13C NMR (100 MHz, CDCl3): 14.35 (C17, N=C–CH3), 22.12 (C7 cyclohexeno), 22.43 (C8 cyclohexeno), 22.91 (C3–C5 piperidinyl), 24.57 (C6 cyclohexeno), 26.09 (C9 cyclohexeno), 26.81 (C14 CH2), 50.96 (C16, COCH3), 67.10 (C2, C6 piperidinyl), 111.61 (C3, C4 pyrrolyl), 123.02 (C5a), 123.98 (C2, C5 pyrrolyl), 128.15 (C9b), 129.86 (C9a), 131.43 (C2), 139.47 (C13), 143.61 (C1), 148.50 (C3a), 157.43 (C5), 162.88 (2C=O, C10, C15) ppm.

(3,5-Dimethyl-1H-pyrazol-1-yl)(5-(piperidinyl)-1-(1H-pyrrolyl)-6,7,8,9-tetrahydro thieno[2,3-c]isoquinolin-2-yl)methanone (12)

A solution of 11 (1.00 g, 2.10 mmol) in acetic acid (10 mL) was refluxed for 1 h. The solid product formed during reflux was collected, dried, and recrystallized from ethanol as white needles in 58% (0.56 g) yield, mp 238–240 °C. Anal. Calcd for C26H29N5OS (459.61) C, 67.95; H, 6.36; N, 15.24; S, 6.98%. Found: C, 67.83; H, 6.24; N, 15.12; S, 6.86%. FT-IR ν (cm–1): 2941, 2847, 2559 (CH-aliphatic), 1683 (CO), 1661 (C=N). 1H NMR (400 MHz, CDCl3): δ 1.25–1.27 (s, 3H, CH3: C3 pyrazolyl), 1.61–1.65 (m, 9H, 3CH2: C3–C5 piperidinyl + CH3: C5 pyrazolyl), 1.70–1.72 (m, 4H, 2CH2: C8, C7 cyclohexeno), 2.31–2.33 (m, 2H, CH2: C9 cyclohexeno), 2.63–2.64 (m, 2H, CH2: cyclohexeno), 3.19–3.22 (m, 4H, 2CH2: C2, C6 piperidinyl), 6.34–6.35 (m, 2H, C3, C4 pyrrolyl), 6.71–6.72 (m, 2H, C2, C5 pyrrolyl), 7.27 (s, 1H, CH pyrazolyl) ppm. 13C NMR (100 MHz, CDCl3): 22.09 (C5, CH3 pyrazolyl), 22.12 (C3, CH3 pyrazolyl), 22.39 (C7 cyclohexeno), 24.57 (C8 cyclohexeno), 26.08 (C3–C5 piperidinyl), 26.84 (C6 cyclohexeno), 29.71 (C9 cyclohexeno), 50.94 (C2, C6 piperidinyl), 109.57 (C3, C4 pyrrolyl), 122.73 (C4, CH pyrazolyl), 122.89 (C5a, C2, C5 pyrrolyl), 123.70 (C9b), 123.92 (C9a), 137.88 (C3 pyrazolyl), 144.66 (C2), 157.02 (C5 pyrazolyl, C1), 163.33 (C5, C3a), 164.90 (C10, C=O) ppm.

N′-Ethoxymethylene-2-(5-(piperidinyl)-1-(1H-pyrrolyl)-6,7,8,9-tetrahydrothieno[2,3-c]isoquinoline-2-yl)carbohydrazide (13)

The carbohydrazide 10 (2.00 g, 5.00 mmol) and triethyl orthoformate (1.50 mL, 0.70 mol) in the presence of catalytic drops of glacial acetic acid (0.25 mL) were refluxed for 30 min. The precipitated solid which was separated out on heating was filtered, dried, and recrystallized from dioxane as green crystals in 87% (1.75 g) yield, mp 198–200 °C. Anal. Calcd for C24H29N5O2S (451.59) C, 63.83; H, 6.47; N, 15.51; S, 7.10%. Found: C, 63.70; H, 6.58; N, 15.43; S, 7.00%. FT-IR ν (cm–1): 3332 (NH), 3123, 3100 (CH-pyrrolyl), 2944, 2850 (CH-aliphatic), 1664 (CONH), 1624 (C=N). 1H NMR (400 MHz, CDCl3): δ 1.31–1.34 (t, J = 7.10 Hz, 3H, CH3 ester), 1.46–1.62 (m, 6H, 3CH2: C3–C5 piperidinyl), 1.70–1.75 (m, 4H, 2CH2: C7, C8 cyclohexeno), 2.23–2.24 (m, 2H, CH2: C6 cyclohexeno), 2.63–2.65 (m, 2H, CH2: C9 cyclohexeno), 3.15–3.17 (m, 4H, 2CH2: C2, C6 piperidinyl), 4.00–4.05 (q, J = 7.10 Hz, 2H, CH2 ester), 6.42–6.43 (m, 2H, C3, C4 pyrrolyl), 6.51 (s, 1H, N=CH), 6.81–6.82 (m, 2H, C2, C5 pyrrolyl), 8.53 (s, 1H, NH) ppm. 13C NMR (100 MHz, CDCl3): 15.52 (C16, CH3 ester), 21.84 (C7 cyclohexeno), 22.16 (C8 cyclohexeno), 22.42 (C4 piperidinyl), 24.59 (C3, C5 piperidinyl), 26.13 (C6 cyclohexeno), 26.64 (C9 cyclohexeno), 51.02 (C2, C6 piperidinyl), 67.77 (C15 OCH2), 111.37 (C3, C4 pyrrolyl), 122.99 (C5a), 123.66 (C2, C5 pyrrolyl), 123.73 (C9b), 130.54 (C9a), 130.93 (C2), 143.63 (C13 N=CH), 144.90 (C1), 155.79 (C3a), 157.27 (C5), 162.98 (C10 CO) ppm.

Procedure of In Vitro Antibacterial Assay

All microorganisms utilized were attained from the culture combination of Microbiology Department, Faculty of Medicine, Assiut University. A variety of Gram-negative (E. coli and Pseudomonas aeruginosa) and Gram-positive bacterial strains (S. aureus and B. cereus) was used to measure the efficacy of various synthesized compounds utilizing 5 mL solution of the synthesized compounds in dimethyl sulfoxide (DMSO) as a solvent. The examined compounds were primarily estimated by maximum concentration at 100 μg/mL in DMSO and amoxicillin as a reference. The sterile medium (Nutrient Agar Medium, 15 mL) in every Petri dish was uniformly smeared with cultures of Gram-positive and Gram-negative bacteria. The plates were incubated at 37 ± 2 °C for 24 h.

Procedure of In Vitro Antifungal Assay

The fungal strains (C. albicans, A. flavus, G. candidium, and T. rubrum) were gained from selected conditions of human dermatophytosis (Assiut University Mycological Center, AUMC). The fungal kinds were developed in sterilized 9 cm Petri dishes containing Sabouraud’s dextrose agar (SDA) supplemented with 0.05% of amoxicillin to inhibit contamination of bacteria.40 The agar disks (10 mm diameter) containing spores from these cultures were aseptically transferred to screw-topped vials containing 20 mL sterile distilled water. After shaking, samples of the spore suspension (1 mL) were pipetted into sterile Petri dishes, followed by the addition of 15 mL liquefied SDA medium which was then left to solidify. The screened compounds 5a, 6, 7a, 7b, and 7c and the reference drug (clotrimazole) were dissolved in DMSO to provide 2.0% concentration. The inoculated plates were incubated at room temperature for 4 days.

Antibacterial and antifungal activities of the tested compounds were determined consistent with the strategy described by Kwon-Chung and Bennett39 using 5 mm diameter wells loaded with 50 μL of the solution under study. Furthermore, stock solutions of the standard drugs (amoxicillin and clotrimazole) were prepared in DMSO and 100 μg/mL concentration utilized for antimicrobial and antifungal efficiency. The zones of inhibition were determined and listed in Tables 1 and 2, respectively.

Procedure of In Vitro Inhibition Zone and MIC

The examined compounds (5a, 6, 7a, 7b, and 7c) to be screened were dissolved in DMSO to afford a solution of 2% concentration. Filter paper discs (Whatman no. 3) with about 5 mm in diameter were saturated with 15 mL of the tested compound solutions and then placed on the surface of the previously prepared agar plates which seeded by the tested bacteria. To ensure complete contact with the agar surface, each disc was immersed down. Subsequently, the agar plates were incubated at 37 °C for 16–18 h for bacteria and then at room temperature. The zones’ diameters of the compound inhibition were measured and recorded in the previous table. A similar procedure39,40 was implemented for commercial antibiotics amoxicillin which was utilized as the positive control for bacteria. The MIC of every compound was determined by the microdilution method. The biologically active compounds were successively diluted in DMSO and incubated with 10 mL broth tubes vaccinated with the examined culture for 24 h. MIC of each compound was measured as the lowest concentration (μg mL–1) that did not display any visible bacteria.

Acknowledgments

The authors are very grateful to Prof. Dr./Etaify A. Bakhite, Chairman of Chemistry Department, for the facilities provided. Dr./Hend Abo El-Maged, Lecturer at faculty of Pharmacy, Assiut University, is also acknowledged for her assistance in making the 2D-QSAR model. Also, we acknowledge the staff members of the Chemistry Department for their sincere effort during this work.

Supporting Information Available

The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acsomega.9b02604.

  • 1H, 13C NMR, FT-IR, and mass spectra for the newly synthesized compounds (PDF)

This work was not funded by any agency.

The authors declare no competing financial interest.

Supplementary Material

ao9b02604_si_001.pdf (4.7MB, pdf)

References

  1. Bentley K. W. β-Phenylethylamines and the isoquinoline alkaloids. Nat. Prod. Rep. 2005, 22, 249–268. 10.1039/b316108k. [DOI] [PubMed] [Google Scholar]
  2. Castillo J.-C.; Jiménez E.; Portilla J.; Insuasty B.; Quiroga J.; Moreno-Fuquen R.; Kennedy A. R.; Abonia R. Application of a catalyst-free Domino Mannich/Friedel-Crafts alkylation reaction for the synthesis of novel tetrahydroquinolines of potential antitumor activity. Tetrahedron 2018, 74, 932–947. 10.1016/j.tet.2017.12.049. [DOI] [Google Scholar]
  3. Pingaew R.; Mandi P.; Nantasenamat C.; Prachayasittikul S.; Ruchirawat S.; Prachayasittikul V. Design, synthesis and molecular docking studies of novel N-benzenesulfonyl-1,2,3,4-tetrahydroisoquinoline-based triazoles with potential anticancer activity. Eur. J. Med. Chem. 2014, 81, 192–203. 10.1016/j.ejmech.2014.05.019. [DOI] [PubMed] [Google Scholar]
  4. Ko Y. S.; Park E. J.; Kim Y. M.; Kim H. J.; Yun-Choi H.; Lee D. H.; Chang K. C. A limited series of synthetic tetrahydroisoquinoline alkaloids reduce inflammatory gene iNOS via inhibition of p-STAT-1 and suppress HMGB1 secretion in LPS-treated mice lung tissue. Int. Immunopharmacol. 2017, 52, 297–304. 10.1016/j.intimp.2017.09.025. [DOI] [PubMed] [Google Scholar]
  5. Fodale V.; Santamaria L. B.. Obstetric Anesthesia Handbook. Eur. J. Anaesthesiol, 5th ed.; Datta S.; Kodali B. S.; Segal S.; Academic Press: New York, 2002; pp 466–473. [Google Scholar]
  6. Siegfried L.; Helmut V.; Guenther W.; Thomas S.; Eckart S.; Dieter L.; Gunter L. Ger (East) DD. 1988, 258, 013; Appl. 1987, 300, 312; 5. Chem. Abstr. 1989, 110, 75554g. [Google Scholar]
  7. Scott J. D.; Williams R. M. Chemistry and biology of the tetrahydroisoquinoline antitumor antibiotics. Chem. Rev. 2002, 102, 1669–1730. 10.1021/cr010212u. [DOI] [PubMed] [Google Scholar]
  8. Gao M.; Kong D.; Clearfield A.; Zheng Q.-H. Synthesis of carbon-11 and fluorine-18 labeled N-acetyl-1-aryl-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline derivatives as new potential PET AMPA receptor ligands. Bioorg. Med. Chem. Lett. 2006, 16, 2229–2233. 10.1016/j.bmcl.2006.01.042. [DOI] [PubMed] [Google Scholar]
  9. Sano T.; Shinohara T.; Takeda A.; Toda J.; Terasawa N. A highly efficient synthesis of 1-methyl-, 1-benzyl-, and 1-phenyl-1,2,3,4-tetrahydroisoquinolines by a modified pummerer reaction. Heterocycles 1997, 46, 555–565. 10.3987/com-97-s70. [DOI] [Google Scholar]
  10. Takada K.; Uehara T.; Nakao Y.; Matsunaga S.; van Soest R. W. M.; Fusetani N. Schulzeines A–C, New α-Glucosidase Inhibitors from the Marine SpongePenares schulzei1. J. Am. Chem. Soc. 2004, 126, 187–193. 10.1021/ja037368r. [DOI] [PubMed] [Google Scholar]
  11. Naoi M.; Maruyama W.; Sasuga S.; Deng Y.; Dostert P.; Ohta S.; Takahashi T.. Neurochem. Int. Pharmacology of Endogenous Neurotoxins: A Handbook; Moser A., Ed.; Academic Press: New York, 1994; Vol. 25; pp 475–481. [DOI] [PubMed] [Google Scholar]
  12. Kato E.; Kimura S.; Kawabata J. Ability of higenamine and related compounds to enhance glucose uptake in L6 cells. Bioorg. Med. Chem. 2017, 25, 6412–6416. 10.1016/j.bmc.2017.10.011. [DOI] [PubMed] [Google Scholar]
  13. Erasto P.; Omolo J.; Sunguruma R.; Munissi J. J.; Wiketye V.; de Konig C.; Ahmed A. F. Evaluation of antimycobacterial activity of higenamine using Galleria mellonella as an in vivo infection model. Nat. Prod. Bioprospect. 2018, 8, 63–69. 10.1007/s13659-018-0152-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Zhang N.; Lian Z.; Peng X.; Li Z.; Zhu H. Applications of Higenamine in pharmacology and medicine. J. Ethnopharmacol. 2017, 196, 242–252. 10.1016/j.jep.2016.12.033. [DOI] [PubMed] [Google Scholar]
  15. Park J.-H.; Hwang I.-C.; Ha N.; Lee S.; Kim J. M.; Lee S. S.; Yu H.; Lim I.-T.; You J.-A.; Kim D.-h. Effects of the anti-sepsis drug, (S)-1-(α-naphthylmethyl)-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline (CKD-712), on mortality, inflammation, and organ injuries in rodent sepsis models. Arch. Pharm. Sci. Res. 2011, 34, 485–494. 10.1007/s12272-011-0318-6. [DOI] [PubMed] [Google Scholar]
  16. Sun X.; Liu M.; Gao L.; Mao Y.; Zhao D.; Zhuang J.; Liu L. A novel tetrahydroisoquinoline (THIQ) analogue induces mitochondria-dependent apoptosis. Eur. J. Med. Chem. 2018, 150, 719–728. 10.1016/j.ejmech.2018.03.017. [DOI] [PubMed] [Google Scholar]
  17. Pradhan S.; Mahaddalkar T.; Choudhary S.; Manhcukonda N.; Reddy Nagireddy P.; Kantevari S.; Lopus M. Elucidation of the Tubulin-targeted Mechanism of Action of 9-(3-pyridyl) Noscapine. Curr. Top. Med. Chem. 2017, 17, 2569–2574. 10.2174/1568026617666170104150304. [DOI] [PubMed] [Google Scholar]
  18. Li L.; Jiao Y.; Jin T.; Sun H.; Li S.; Jin C.; Hu S.; Ji J.; Xiang L. Phenolic alkaloid oleracein E attenuates oxidative stress and neurotoxicity in AlCl3-treated mice. Life Sci. 2017, 191, 211–218. 10.1016/j.lfs.2017.10.019. [DOI] [PubMed] [Google Scholar]
  19. Lin W.; Ma S. Enantioselective synthesis of naturally occurring isoquinoline alkaloids: (S)-(−)-trolline and (R)-(+)-oleracein E. Org. Chem. Front. 2017, 4, 958–966. 10.1039/c7qo00062f. [DOI] [Google Scholar]
  20. Mihoubi M.; Micale N.; Scala A.; Jarraya R.; Bouaziz A.; Schirmeister T.; Risitano F.; Piperno A.; Grassi G. Synthesis of C3/C1-Substituted Tetrahydroisoquinolines. Molecules 2015, 20, 14902–14914. 10.3390/molecules200814902. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Kurnik-Łucka M.; Panula P.; Bugajski A.; Gil K. Salsolinol: an unintelligible and double-faced molecule—lessons learned from in vivo and in vitro experiments. Neurotoxic. Res. 2018, 33, 485–514. 10.1007/s12640-017-9818-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Kovács B.; Megyesi R.; Forró E.; Fülöp F. Efficient lipase-catalysed route for the kinetic resolution of salsolidine and its ß-carboline analogue. Tetrahedron: Asymmetry 2017, 28, 1829–1833. 10.1016/j.tetasy.2017.10.019. [DOI] [Google Scholar]
  23. Chen X.; Zheng X.; Ali S.; Guo M.; Zhong R.; Chen Z.; Zhang Y.; Qing H.; Deng Y. Isolation and Sequencing of Salsolinol Synthase, an Enzyme Catalyzing Salsolinol Biosynthesis. ACS Chem. Neurosci. 2018, 9, 1388–1398. 10.1021/acschemneuro.8b00023. [DOI] [PubMed] [Google Scholar]
  24. Luo J.-K.; Musmar M. J.; Castle R. N. The synthesis of substituted [1]benzothieno[2,3-c]quinolines and theirN-methyl quaternary salts. J. Heterocycl. Chem. 1991, 28, 1309–1313. 10.1002/jhet.5570280524. [DOI] [Google Scholar]
  25. Abdel-rahman A. E.; Bakhite E. A.; Abdel-Moneam M. I.; Mohamed T. A. Synthesis and antibacterial activities of some new thieno [2,3-b]quinolines. Phosphorus, Sulfur Silicon Relat. Elem. 1992, 73, 219–227. 10.1080/10426509208034446. [DOI] [Google Scholar]
  26. Russell R. K.; van Nievelt C. E.; Rampulla R. A.; Klaubert D. H.; Bell S. C. The Synthesis of 2,3-Ring-Fused Analogues of 7-Fluoro-1-methyl-3-(methylsulfinyl)-4(1H)-quinolinone. Synthesis 1992, 1992, 753–755. 10.1055/s-1992-26217. [DOI] [Google Scholar]
  27. Kamal El-Dean A. M.; Radwan Sh. M.; Zaki R. M. Synthesis of Morphlinotetrahydrothieno[2,3-c]isoquinolines. J. Chin. Chem. Soc. 2008, 55, 1290–1299. 10.1002/jccs.200800193. [DOI] [Google Scholar]
  28. Kamal El-Dean A. M.; Radwan Sh. M.; Zaki R. M. Reactions of 1-amino-5-morpholino-6, 7, 8, 9-tetrahydrothieno[2,3-c]isoquinoline-2-carbonitrile. J. Chem. Res. 2010, 34, 596–602. 10.3184/030823410x12868184096970. [DOI] [Google Scholar]
  29. Kamal A. M.; Radwan Sh. M.; Zaki R. M. Synthesis and biological activity of pyrazolothienotetrahydroisoquinoline and [1,2,4]triazolo[3,4-a] thienotetrahydroiso- quinoline derivatives. Eur. J. Med. Chem. 2011, 46, 567–578. 10.1016/j.ejmech.2010.11.036. [DOI] [PubMed] [Google Scholar]
  30. Zaki R. M.; Radwan Sh. M.; Kamal El-Dean A. M. Synthesis and Reactions of 1-Amino-5-morpholin-4-yl-6, 7, 8, 9-tetrahydrothieno[2, 3-c]isoquinoline. J. Chin. Chem. Soc. 2011, 58, 544–554. 10.1002/jccs.201190019. [DOI] [Google Scholar]
  31. Zaki R. M.; Radwan Sh. M.; Kamal El-Dean A. M. Synthesis and reactions of novel Thienotetrahydroisoquinoline compounds. Afinidad 2012, 68, 424–434. [Google Scholar]
  32. Zaki R. M.; Kamal El-Dean A. M.; Radwan S. M. Synthesis and reactions of some new morpholinylpyrrolyl tetrahydrothieno[2,3-c]isoquinoline. J. Adv. Chem. 2014, 10, 2512–2523. 10.24297/jac.v10i3.6659. [DOI] [Google Scholar]
  33. Zaki R. M.; Kamal El-Dean A. M.; Abd El Monem M. I.; Seddik M. A. Novel synthesis and reactions of pyrazolyl-substituted tetrahydrothieno[2,3-c]isoquinoline derivatives. Heterocycl. Commun. 2016, 22, 103–109. 10.1515/hc-2015-0204. [DOI] [Google Scholar]
  34. Zaki R. M.; Radwan S. M.; Kamal El-Dean A. M. A Convenient Synthetic Method and Spectral Characterization of New Tetrahydro[1,3]oxazinothieno[2,3-c]isoquinoline and Its Pyrimidine Derivatives. J. Chin. Chem. Soc. 2017, 64, 1417–1431. 10.1002/jccs.201700232. [DOI] [Google Scholar]
  35. Dimroth O. Ueber intramolekulare Umlagerungen. Umlagerungen in der Reihe des 1, 2, 3-Triazols. Justus Liebigs Ann. Chem. 1909, 364, 183–226. 10.1002/jlac.19093640204. [DOI] [Google Scholar]
  36. Ziegler K.; Eberle H.; Ohlinger H. Über vielgliedrige Ringsysteme. I. Die präparativ ergiebige Synthese der Polymethylenketone mit mehr als 6 Ringgliedern. Justus Liebigs Ann. Chem. 1933, 504, 94–130. 10.1002/jlac.19335040109. [DOI] [Google Scholar]
  37. Stephen H. W.; Wilson F. J. CCCXXXII.-Some thiazole derivatives. Part I. J. Chem. Soc. 1926, 129, 2531–2538. 10.1039/jr9262902531. [DOI] [Google Scholar]
  38. Gewald K. Heterocyclen aus CH-aciden Nitrilen. IV. Addition von Schwefelkohlenstoff an Alkylidenmalonitrile und -cyanessigester. J. Prakt. Chem. 1966, 31, 205–213. 10.1002/prac.19660310312. [DOI] [Google Scholar]
  39. Kwon-Chung K. J.; Bennett J. E.. Principles of Antifungal Therapy. Medical Mycology; Lea & Febiger: Philadelphia, USA, 1992; pp 81–102. [Google Scholar]
  40. Al-Doory Y.Laboratory medical mycology, Lea and Febiger: Philadelphia, USA, 1980; Vol. 20, pp 219–241. [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

ao9b02604_si_001.pdf (4.7MB, pdf)

Articles from ACS Omega are provided here courtesy of American Chemical Society

RESOURCES